Identification of lysosome‐targeting drugs with anti‐inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers

PURPOSE: Most HER2 positive invasive cancers are either intrinsic non-responsive or develop resistance when treated with 1st line HER2 targeting drugs. Both 1st and 2nd line treatments of HER2 positive cancers are aimed at targeting the HER2 receptor directly, thereby strongly limiting the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Malene Bredahl, Postol, Maria, Tvingsholm, Siri, Nielsen, Inger Ødum, Dietrich, Tiina Naumanen, Puustinen, Pietri, Maeda, Kenji, Dinant, Christoffel, Strauss, Robert, Egan, David, Jäättelä, Marja, Kallunki, Tuula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090911/
https://www.ncbi.nlm.nih.gov/pubmed/33939112
http://dx.doi.org/10.1007/s13402-021-00603-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090911/
https://www.ncbi.nlm.nih.gov/pubmed/33939112
http://dx.doi.org/10.1007/s13402-021-00603-2

Ejemplares similares